Biotech · Private company
1ST Biotherapeutics, Inc.
Track this companyFree. Adds 1ST Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- Phase Ia dose-escalation part of FB849 MonotherapyPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Phase Ib dose-expansion of FB849 monotherapyPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Phase IIb dose-escalation part of FB849 in Combination with PembrolizumabPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- FB-101Phase 1 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849PHASE1_PHASE2 · RECRUITING · started Dec 13, 2023ClinicalTrials.gov NCT05761223 · fetched Nov 12, 2026
- Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy SubjectsPHASE1 · COMPLETED · started Oct 14, 2019ClinicalTrials.gov NCT04165837 · fetched Nov 12, 2026